These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11758556)

  • 21. Targeting formulary pull-through strategies: the role of pharmaceutical manufacturers.
    Navarro RP
    Manag Care Interface; 1999 May; 12(5):84-6. PubMed ID: 10537482
    [No Abstract]   [Full Text] [Related]  

  • 22. Networks can avoid antitrust scrutiny.
    Waxman JM
    Provider; 1997 Feb; 23(2):42-5. PubMed ID: 10167120
    [No Abstract]   [Full Text] [Related]  

  • 23. Powerful networks could result in public utility-style regulation of health care.
    Weil TP
    Healthspan; 1995 Feb; 12(2):12-5. PubMed ID: 10166119
    [No Abstract]   [Full Text] [Related]  

  • 24. Reframing the pharmaceutical manufacturer/health plan relationship in managed care.
    Studin I
    Manag Care; 2002 Feb; 11(2):46, 49-54. PubMed ID: 11904913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing injectable drugs: an evolving challenge for pharmacy benefit managers.
    Giaquinta D
    Manag Care Interface; 2002 Dec; 15(12):15-6. PubMed ID: 12530291
    [No Abstract]   [Full Text] [Related]  

  • 26. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 27. Outcomes research: collaboration among academic researchers, managed care organizations, and pharmaceutical manufacturers.
    Kong SX; Wertheimer AI
    Am J Manag Care; 1998 Jan; 4(1):28-34. PubMed ID: 10179904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What benefit managers want from managed pharmacy programs.
    Kretz SE
    AAPPO J; 1991; 1(5):31-9. PubMed ID: 10149643
    [No Abstract]   [Full Text] [Related]  

  • 29. FTC approves Lilly's PCS purchase.
    Scott L
    Mod Healthc; 1995 Aug; 25(32):30. PubMed ID: 10144477
    [No Abstract]   [Full Text] [Related]  

  • 30. Disease management and antikickback regulations.
    Kozma CM
    Manag Care Interface; 2003 Dec; 16(12):34-5. PubMed ID: 14750462
    [No Abstract]   [Full Text] [Related]  

  • 31. Implications for managed care organizations of the Merck and Medco consent.
    Pollard MR; Tilson HH
    Med Interface; 1996 Mar; 9(3):60-2. PubMed ID: 10184511
    [No Abstract]   [Full Text] [Related]  

  • 32. PBMs: ripe for regulation.
    Johnson RS
    Food Drug Law J; 2002; 57(2):323-69. PubMed ID: 12437004
    [No Abstract]   [Full Text] [Related]  

  • 33. A conversation with Debra Dullinger, PharmD.
    Dullinger D
    Med Interface; 1994 Oct; 7(10):71-4. PubMed ID: 10137568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Provider boycotts--a review of the Merck-Medco decision. Merck-Medco Managed Care L.L.C. v. Rite Aid Corporation.
    Becker S
    Health Care Law Mon; 2000 May; ():10-8. PubMed ID: 14743588
    [No Abstract]   [Full Text] [Related]  

  • 35. Access to pharmaceuticals under Medicaid managed care: federal law compiled and state contracts compared.
    Loza EL
    Food Drug Law J; 2000; 55(3):449-76. PubMed ID: 11824469
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacy benefit management: the right Rx?
    Etheredge L
    Res Agenda Brief; 1995 Apr; (1):1-11. PubMed ID: 12856664
    [No Abstract]   [Full Text] [Related]  

  • 37. [What are the economic advantages of Integrated Health Care?].
    Henke KD
    Clin Res Cardiol; 2006 Jan; 95 Suppl 2():II11-12. PubMed ID: 16598562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Legally speaking: Federal Trade Commission issues positive advisory opinions on antitrust implications of clinical integration.
    Wright R
    J Ark Med Soc; 2009 Oct; 106(4):88-9. PubMed ID: 19813398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weighing the evidence: trends in managed care formulary decision making.
    de Lissovoy G
    J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated health management delivery systems.
    Navarro R
    Med Interface; 1994 Aug; 7(8):63-4, 67-9. PubMed ID: 10136818
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.